Kefadol — Competitive Intelligence Brief

Kefadol (CEFAMANDOLE NAFATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cefamandole nafate. Area: Immunology.

marketed cefamandole nafate Bacterial penicillin-binding protein Immunology Small molecule

Target snapshot

Kefadol (CEFAMANDOLE NAFATE) — Eli Lilly. Kefadol works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kefadol TARGET	CEFAMANDOLE NAFATE	Eli Lilly	marketed	cefamandole nafate	Bacterial penicillin-binding protein	1978-01-01
CEFPIRAMIDE	CEFPIRAMIDE		marketed	cefpiramide	Bacterial penicillin-binding protein	1989-01-01
CEFOTIAM	CEFOTIAM		marketed	cefotiam	Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein	1988-01-01
CEFMENOXIME	CEFMENOXIME		marketed	cefmenoxime	Bacterial penicillin-binding protein	1987-01-01
Bl-S786R	CEFORANIDE		marketed	ceforanide	Bacterial penicillin-binding protein, Penicillin-binding protein 1A	1984-01-01
Cefobid	CEFOPERAZONE		marketed	Cephalosporin Antibacterial	Bacterial penicillin-binding protein, Penicillin-binding protein 1A	1982-01-01
Kafocin	cefaloglycin	Eli Lilly	marketed	cefaloglycin	Bacterial penicillin-binding protein	1970-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cefamandole nafate class)

1. Eli Lilly · 1 drug in this class